Abstract
Heparanase promotes tumorigenesis, angiogenesis, and metastasis. Here, we conducted a study based on systematic review and the Cancer Genome Atlas (TCGA) data that examined heparanase expression in clinical samples to determine its prognostic value. According to the meta-analysis and TCGA data, we found that heparanase expression was up-regulated in most breast cancer specimens, and elevated heparanase expression was associated with increased lymph node metastasis, larger tumor size, higher histological grade, and poor survival. These results suggest that targeting heparanase might improve treatments for breast cancer patients.
Highlights
Despite significant progress in the diagnosis and treatment of breast cancer in recent years, it remains the leading cause of cancer-related death in women worldwide [1]
According to the meta-analysis and the Cancer Genome Atlas (TCGA) data, we found that heparanase expression was up-regulated in most breast cancer specimens, and elevated heparanase expression was associated with increased lymph node metastasis, larger tumor size, higher histological grade, and poor survival
We found that HPSE was overexpressed in breast cancer tissue compared to normal breast tissue
Summary
Despite significant progress in the diagnosis and treatment of breast cancer in recent years, it remains the leading cause of cancer-related death in women worldwide [1]. The identification of new molecular targets with high prognostic values, targets related to invasion and metastasis, wound help to improve breast cancer treatment. The activity of heparanase (HPSE), the only endoglucuronidase that cleaves HS, is closely related to growth and metastasis in tumor cells [8,9,10]. Large preclinical studies have shown that HPSE can promote tumor cell metastasis by degrading the ECM, which leads to the activation of HS-bound cytokines and boosts cell proliferation and tumor angiogenesis [11,12,13]. Some evidence suggests that high HPSE expression is correlated with increases in tumor cell metastasis and poor prognosis [10, 14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
